Conference Coverage

Treating Bipolar Depression Depends on Evidence, Judgment


 

EXPERT ANALYSIS FROM THE ANNUAL CONGRESS OF THE EUROPEAN COLLEGE OF NEURO-

PSYCHOPHARMACOLOGY

Dr. Nierenberg said he has a patent pending on combined treatment of mood disorders with buspirone, bupropion, and melatonin, and he co-owns a copyright on a structured clinical interview for the Montgomery-Åsberg Depression Rating Scale. He said he has received honoraria from Eli Lilly, AstraZeneca, Forest, and Janssen, and that he has received research grants from Pam Labs, Pfizer, and Shire.

Pages

Recommended Reading

Short Course of Escitalopram Reduces Fear in Depression
MDedge Psychiatry
Depression Derails Truthful Talk to Physicians
MDedge Psychiatry
Sertraline Added to Therapy May Fall Short in Postpartum Depression
MDedge Psychiatry
Behavioral Strategy Helps Inpatients With Depression
MDedge Psychiatry
Does a Bipolar Disorder and Intelligence Link Matter?
MDedge Psychiatry
SSRIs, Periodic Limb Movements of Sleep Linked in Children
MDedge Psychiatry
Depressed Mood, RA Disease Activity Linked
MDedge Psychiatry
Off-Label Use of Atypical Antipsychotics Minimally Effective
MDedge Psychiatry
Quo vadis, psychopharmacology?
MDedge Psychiatry
A curious case of depression
MDedge Psychiatry